<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797740</url>
  </required_header>
  <id_info>
    <org_study_id>MS700568_0213</org_study_id>
    <nct_id>NCT05797740</nct_id>
  </id_info>
  <brief_title>Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)</brief_title>
  <official_title>Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to describe participants characteristics that can predict the safety and&#xD;
      effectiveness of cladribine tablets, as assessed by time-to-discontinuation of treatment with&#xD;
      cladribine tablets, and to assess other patient-reported, clinical, and imaging outcomes in&#xD;
      participants with relapsing multiple sclerosis (RMS) in the long term, in a real-world&#xD;
      setting.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 26, 2023</start_date>
  <completion_date type="Anticipated">August 11, 2028</completion_date>
  <primary_completion_date type="Anticipated">August 11, 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Discontinuation of Treatment with Cladribine tablets</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants Receiving Each of The Possible Number of Annual Treatment Courses with Cladribine Tablets</measure>
    <time_frame>Baseline, 12 months, 24 months, 36 months and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Cladribine Dose</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Relapses</measure>
    <time_frame>Baseline, 12 months, 24 months, 36 months and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Severe Relapses</measure>
    <time_frame>Baseline, 12 months, 24 months, 36 months and 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free From Relapse</measure>
    <time_frame>Year 2 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Onset of Relapse to Recovery</measure>
    <time_frame>Up to Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized Relapse Rate (ARR)</measure>
    <time_frame>At Year 2 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free From Magnetic Resonance Imaging (MRI) Activity</measure>
    <time_frame>At Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Minimal MRI Activity (=&lt; 2 New T2 Lesions)</measure>
    <time_frame>At Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timed 25-Foot Walk (T25FW) Score</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Increase and Decrease in Timed 25-Foot Walk (T25FW) Score of At Least 20% From Baseline at Year 1, 2, 3 and 4</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-Hole Peg Test (9HPT) Score</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with an Increase and Decrease in 9-Hole Peg Test (9HPT) Score of At Least 20% From Baseline at Year 1, 2, 3 and 4</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Progressed, Improved, or Stable Disability as Assessed by Expanded Disability Status Scale (EDSS) Confirmed Over 6 Months</measure>
    <time_frame>Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Disability Progression, Improvement, or Stability Confirmed Over 6 Months as Assessed by T25FW Score</measure>
    <time_frame>Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Sustained Disability Progression, Improvement, or Stability Confirmed Over 6 Months as Assessed by 9HPT Score</measure>
    <time_frame>Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Minimal Evidence of Disease Activity (MEDA)</measure>
    <time_frame>Year 2 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With No Evidence of Disease Activity (NEDA-3)</measure>
    <time_frame>Year 2 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Impact Scale (MSIS-29) Physical Domain Score, Psychological Domain Score and Total Score</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol 5-Dimensions (EQ-5D-5L) Score</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Satisfaction, Effectiveness, Side Effects, and Convenience Domain Scores of Treatment Satisfaction Questionnaire for Medication (TSQM)</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Cost of Disease-Modifying Treatment (DMTs)</measure>
    <time_frame>Up to 48 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol Visual Analog Scale (EQ-VAS) Score</measure>
    <time_frame>Baseline, Year 1, Year 2, Year 3 and Year 4</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Single cohort</arm_group_label>
    <description>This is a single cohort study enrolling Participants with relapsing multiple sclerosis (RMS), who are prescribed treatment with cladribine tablets in routine clinical practice following the summary of product characteristics (SmPC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mavenclad</intervention_name>
    <description>This is an observational study, participants who received cladribine tablets in routine clinical practice following the SmPC will be included.</description>
    <arm_group_label>Single cohort</arm_group_label>
    <other_name>Cladribine</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study enrolls participants with a confirmed diagnosis of RMS (with high disease&#xD;
        activity) who have been prescribed, have initiated, or have completed/discontinued&#xD;
        treatment with cladribine tablets per the decision of the treating physician.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult participants, male or female patients ≥ 18 years old at index date&#xD;
&#xD;
          -  Participants must voluntarily give written informed consent form (ICF). Patients must&#xD;
             read and fully understand the ICF&#xD;
&#xD;
          -  Participants with confirmed diagnosis of RMS at index date, diagnosed by the treating&#xD;
             physician according to applicable clinical practice guidelines (currently McDonald&#xD;
             2017 criteria), with high disease activity.&#xD;
&#xD;
          -  Required historical data should be available: number of relapses in the 12 months&#xD;
             prior to index date, DMTs taken prior to index date, date of MS diagnosis, and data of&#xD;
             at least 1 MRI prior to index date as specified in the drug Summary of Product&#xD;
             Characteristics (SmPC)&#xD;
&#xD;
          -  Fulfillment of the indication for treatment with cladribine tablets at index date, per&#xD;
             standard of care in accordance with the local SmPC&#xD;
&#xD;
          -  Meeting 1 of the following criteria:&#xD;
&#xD;
               -  Prospective participants: Having been prescribed with cladribine tablets or&#xD;
                  having taken at least one dose of cladribine tablets, with enrollment date prior&#xD;
                  to the second treatment week&#xD;
&#xD;
               -  Retrospective participants: Having taken at least one dose of cladribine tablets,&#xD;
                  with enrollment date during or after the second treatment week but not more than&#xD;
                  3 years after the first dose of cladribine tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to use of cladribine tablets according to the SmPC.&#xD;
&#xD;
          -  Any participant who had the first dose of cladribine tablets more than 3 years prior&#xD;
             to enrollment&#xD;
&#xD;
          -  Any participant who is pregnant or plans to breast-feed while taking cladribine&#xD;
             tablets, or any patient who or whose partner plans to become pregnant in Year 1 or&#xD;
             within 6 months after the last dose in Year 2, or any participants who is unwilling or&#xD;
             unable to use contraception per the SmPC&#xD;
&#xD;
          -  Have participated or participating in an interventional study since cladribine tablet&#xD;
             initiation, in which participant assessment and/or treatment may be dictated by a&#xD;
             protocol&#xD;
&#xD;
          -  Participants who, at the discretion of the Investigator, will not be able to provide&#xD;
             reliable information for the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Communication Center</last_name>
    <phone>+496151725200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCL Saint Luc</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge vzw</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liege 1</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN u sv. Anny Brno</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FN Hradec Králové</name>
      <address>
        <city>Hradec Kralove</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Ostrava</name>
      <address>
        <city>Ostrava</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Teplice</name>
      <address>
        <city>Teplice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Thrace, Medical School - Neurology Department, Alexandroupoli</name>
      <address>
        <city>Alexandroupoli</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>251 General Air Force Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aiginiteio' Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Attikon</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Miliary Hospital of Athens &quot;401&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Oncology Hospital &quot;Agioi Anargyroi&quot;</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larissa</name>
      <address>
        <city>Larissa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital &quot;Agios Andreas&quot;</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Patras</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHEPA University Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens G.Gennimatas</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interbalkan Hospital of Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papageorgiou General Hospital Thessaloniki</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Luke's Clinic</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland</name>
      <address>
        <city>Sittard-Geleen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniwersytecki Szpital Kliniczny w Bialymstoku</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Academy Neurology Clinic</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Nr 1 Pomorskiego Uniwersytetu Medycznego w Szczecinie</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar e Universitario de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Lisboa Norte Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário Lisboa Central - Hospital dos Capuchos</name>
      <address>
        <city>Lisbon</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de São João E. P. E.</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Greece</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>March 22, 2023</study_first_submitted>
  <study_first_submitted_qc>March 22, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>March 22, 2023</last_update_submitted>
  <last_update_submitted_qc>March 22, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>Relapsing Multiple Sclerosis</keyword>
  <keyword>Mavenclad</keyword>
  <keyword>Cladribine Tablets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

